NEW YORK, NY--(Marketwire -05/03/12)- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will look to benefit the Biotechnology Industry going forward "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system," BIO President and CEO Jim Greenwood stated in a press release. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on AEterna Zentaris Inc. (AEZS) and Zalicus Inc. (ZLCS - News).
Access to full reports can be found at:
"Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood. The America Invents Act (AIA) will shift the patent system from a "first to invent" to a "first to file" system, the first major change to the patent system in over 60 years. Under the "first to invent" system the first inventor to file for a patent will be awarded priority, regardless if the inventor was the first to invent it. Most major countries are already following the "first to file" patent system.
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
AEterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. AEterna Zentaris' pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The company will announce its first quarter 2012 financial and operating results before market open on Wednesday, May 9, 2012.
Zalicus, a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, recently announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive®, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.ParagonReport.com/disclaimer